Ulf Boemer

Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction

R.C. Hillig, Brice Sautier, Jens Schroeder et al. · Proceedings of the National Academy of Sciences · 2019 · 363 citations · Full text

Characterization of novel MPS1 inhibitors with preclinical anticancer activity

Mohamed Jèmaà, Lorenzo Galluzzi, Oliver Kepp et al. · Cell Death and Differentiation · 2013 · 109 citations · Full text

Novel Mps1 Inhibitors, Medicine, Tumor Targeting +5

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models

Sylvia Grünewald, Oliver Politz, Sebastian Bender et al. · International Journal of Cancer · 2019 · 89 citations · Full text

Novel Pan-fgfr Inhibitor, Tumor Biology, Fgfrs 1 +14

Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2-<i>d</i>]pyrimidine Based <i>in Vitro</i> Probe <b>BAY-885</b> for the Kinase ERK5

Duy Nguyen, Clara Lemos, Lars Wortmann et al. · Journal of Medicinal Chemistry · 2018 · 40 citations · Full text

Cell Death, Molecular Biology, Chemical Biology +23

A One-Day, Dispense-Only IP-One HTRF Assay for High-Throughput Screening of G _{<i>α</i> q} Protein-Coupled Receptors: Towards Cells as Reagents

Christian Bergsdorf, Carmen Kropp-Goerkis, Irene Kaehler et al. · Assay and Drug Development Technologies · 2008 · 28 citations